Bacteriophage MarketThe global bacteriophage market, valued at USD 45.07 million in 2023, is projected to reach USD 68 million by 2033, growing at a CAGR of 4.2% over the forecast period. The ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

Sonnet's F H AB platform consists of a single, fully human construct of a F H AB antibody fragment that has high affinity to bind to human albumin. The platform provides an off-the-shelf lock and load ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can ...

Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a ...